Beyond hairy cell: The activity of cladribine in other hematologic malignancies

Blood

Volumn 116, Issue 16, 2010, Pages 2884-2896

  Sigal, Darren S ^a   Miller, Heather J ^a   Schram, Ethan D ^a   Saven, Alan ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEOXYADENOSINE DIPHOSPHATE; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; APOPTOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; BACTERIAL INFECTION; CANCER RISK; CELL DEATH; CELL DIVISION; CHRONIC DISEASE; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOPENIA; DNA REPLICATION; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FEVER; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HAIR CELL; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPROPHYLAXIS; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTOMA; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PURE RED CELL ANEMIA; REVIEW; STEVENS JOHNSON SYNDROME; STROKE; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 77958155612     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-246140     Document Type: Review

References (123)

1. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2(7786):1067-1069.
2. Cohen A, Hirschhorn R, Horowitz SD, et al. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978;75(1):472-476. (Pubitemid 8287550)
3. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleosidase kinase(s). Proc Natl Acad Sci U S A. 1977;74(12):5677-5681.
4. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980;77(11):6865-6869. (Pubitemid 11219046)
5. Christensen LF, Broom AD, Robins MJ, Bloch A. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- and -D-erythro-pentofuranosyl) purines. J Med Chem. 1972;15(7):735-739.
6. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5):891-896. (Pubitemid 46606450)
7. Vijayalakshmi DA, Belt JA. Sodium-dependent nucleoside transport in mouse intestinal epithelial cells. J Biol Chem. 1988;263(36):19419-19423.
8. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340(8825):952-956.
9. Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: not just another purine analogue? Expert Opin Investig Drugs. 2009;18(8):1169-1181.
10. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62(4):737-743.
11. Kawasaki J, Carera CJ, Piro LD, Saven A, Kipps T, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993;81(3):597-601.
12. Arner ES, Flygar M, Bohman C, Wallstrom B, Eriksson S. Deoxycytidine kinase is constitutively expressed in human lymphocytes: consequences for compartmentation effects, unscheduled DNA synthesis, and viral replication in resting cells. Exp Cell Res. 1988;178(2):335-342.
13. Lotfi K, Juliusson G, Albertioni F. Pharmacological basis for cladribine resistance. Leuk Lymphoma. 2003;44(10):1705-1712.
14. Månsson E, Flordal E, Liliemark J. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 2003;65(2):237-247.
15. Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine in humans. Proc Natl Acad Sci U S A. 1984;81(7):2232-2236. (Pubitemid 14146638)
16. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985;75(2):377-383.
17. Carson DA, Seto C, Wasson DB, Carrera CJ. DNA strand breaks, NAD metabolism and programmed cell death. Exp Cell Res. 1986;164(2):273-281.
18. Marzo I, Pérez-Galán P, Giraldo P. Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J. 2001;359(Pt 3):537-546.
19. Hentosh P, Grippo P. Template 2-chloro-2-deoxyadenosine monophosphate inhibits in vitro DNA synthesis. Mol Pharmacol. 1994;45(5):955-961. (Pubitemid 24155786)
20. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2-deoxyadenosine 5-triphosphate and cytochrome c. Proc Natl Acad Sci U S A. 1998;95(16):9567-9571.
21. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem. 2000;275(1):29-34.
22. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2- deoxyadenosine in humans. Cancer Res. 1991;51(20):5570-5572.
23. Sonderegger T, Betticher DC, Cerny T, Lauterburg BH. Pharmacokinetics of 2-CDA administered subcutaneously or by continuous intravenous infusion. Cancer Chemother Pharmacol. 2000;46(1):40-42. (Pubitemid 30432173)
24. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol. 1992;10(10):1514-1518.
25. Saven A, Kawasaki H, Carrera CJ. 2-Chlorodeoxyadenosine dose escalation in non-hematologic malignancies. J Clin Oncol. 1993;11(4):671-678.
26. Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol. 1992;10(3):371-377.
27. Morton J, Taylor K, Bunce I, et al. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Br J Haematol. 1996;95(1):110-115.
28. Robak T, Gora-Tybor J, Krykowski E, et al. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1997;26(1):99-105.
29. Hickish T, Serafinowski P, Cunningham D, et al. 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer. 1993;67(1):139-143.
30. Hoffman M, Tallman MS, Hakimian D, et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol. 1994;12(4):788-792.
31. Liliemark J, Porwit A, Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1997;25(3):313-318.
32. Kong LR, Huang CF, Hakimian D, et al. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated advanced, indolent non-Hodgkin's lymphoma. Cancer. 1998;82(5):957-964.
33. Tupule A, Schiller G, Harvey-Buchanan LA, et al. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer. 1998;83(11):2370-2376.
34. Tondini C, Balzarotti M, Rampinelli I, et al. Fludarabine and cladribine in relapsed refractory low-grade non-Hodgkin's lymphoma: a Phase II randomized study. Ann Oncol. 2000;11(2):231-233.
35. Ogura M, Morishima Y, Kobayashi Y, et al. Durable response but prolonged cytopenias after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol. 2004;80(3):267-277.
36. Tobinai K, Watanabe T, Tanimoto K, et al. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. Cancer Sci. 2009;100(7):1344-1350.
37. Van Den Neste E, Michaux L, Layios N, et al. High incidence of complications after 2-chloro-2′-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;83(6):356-363.
38. Saven A, Lee T, Kosty MP, et al. Cladribine and mitoxantrone dose escalation in indolent non Hodgkin's lymphoma. J Clin Oncol. 1996;14(7)2139-2144. (Pubitemid 26230117)
39. Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer. 1999;79(7):1215-1219.
40. Robak T, Gora-Tybor J, Urbańska-Ryś H, Krykowski E. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1999;32(3):359-363.
41. Rummel MJ, Chow KU, Karakas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer. 2002;38(13):1739-1746.
42. Robak T, Smolewski P, Urbanska-Rys H, Gora-Tybor J, Blonski JZ, Kasznicki M. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma. 2004;45(5):937-944.
43. Robak T, Smolewski P, Cebula B, et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer. 2006;107(7):1542-1550.
44. Laurencet F, Ballabeni P, Rufener B, et al. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta Haematol. 2007;117(1):40-47.
45. Inwards DJ, Fishkin PA, Hillman DW, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008;113(1):108-116.
46. Blum KA, Johnson JL, Niedzwiecki D, et al. Cancer and Leukemia Group B Study 9153. Prolonged follow-up after initial therapy with 2- chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer. 2006;107(12):2817-2825.
47. Rummel MJ, Chow KU, Jäger E, et al. Intermittent 2-hour infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma. 1999;35(1):129-138. (Pubitemid 29454410)
48. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood. 1995;86(5):1710-1716.
49. Betticher DC, Zucca E, von Rohr A, et al. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol. 1996;7(8):793-799.
50. Canfield VA, Vose J, Guiney P, Bennett B, Nichols C. 2- Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas. Leuk Lymphoma. 1997;24(3):335-339. (Pubitemid 27101605)
51. Fridrik MA, Jäger G, Kienzer HR, et al. Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine) - 2 h infusion for 5 days - as first-line treatment for advanced low grade non-Hodgkin's lymphoma. Eur J Cancer. 1998;34(10):1560-1564.
52. Liliemark J, Martinsson U, Cavallin-Stahl E, et al. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1998;30(5):573-581.
53. Rummel MJ, Chow KU, Jäger E, et al. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol. 1999;10(1):115-117. (Pubitemid 29090601)
54. Jäger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20(18):3872-3877.
55. Lefrère F, Hermine O, François S, et al. Lack of efficacy of 2-chlorodeoxyadenosine in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2000;40(1):113-117.
56. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994;12(12):2694-2698.
57. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med. 1993;118(3):195-198.
58. Fridrik MA, Jäger G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenström's disease with cladribine. Ann Hematol. 1997;74(1):7-10. (Pubitemid 27050902)
59. Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol. 1998;103(3):690-695.
60. Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol. 1999;63(1):35-41.
61. Kalinka-Warzocha E, Wajs J, Lech-Maranda E, et al. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Cancer. 2008;113(2):367-375.
62. Hagenbeek A, Eghbali H, Monfardini S, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage II and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(10):1590-1596.
63. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
64. Vijay A, Gertz MA, Waldenstrom macroglobulinemia. Blood. 2007;109(12):5096-5103.
65. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27(1):120-126.
66. Tsimberidou AM, Wen S, O'Brien S, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolyte lymphocyte counts in 2126 patients: 20 years of experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol. 2007;25(29):4648-4656.
67. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-798.
68. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088.
69. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-B-D-arabinosyl-2-fluoroadenine. Blood. 1993;81(1):143-150.
70. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 2000;96(10):3537-3543.
71. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2- Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma. 1991;5[suppl]:133-138.
72. Robak T, Blasinska-Morawiec M, Krykowski E, et al. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 100 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1996;22(5):509-522.
73. Robak T, Góra-Tybor J, Lech-Marańda E, Bloń ski JZ, Kasznicki M. Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol. 2001;66(3):188-194.
74. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia: updated results of the multicentre study of 378 patients. Br J Haematol. 2000;108(2):357-368.
75. Tallman MS, Hakimian D, Zanzig C, et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 1995;13(4):983-988.
76. Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol. 1996;7(4):373-379.
77. Montillo M, Tedeschi A, O'Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer. 2003;97(1):114-120. (Pubitemid 36033870)
78. Karlsson K, Stromberg M, Liliemark J, et al. Oral cladribine for B-cell chronic lymphocytic leukemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients. Br J Haematol. 2002;116(3):538-548.
79. Rondelli D, Lauria F, Zinzani PL, et al. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haematol. 1997;58(1):46-50.
80. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 1988;72(3):1069-1073.
81. Juliusson G, Liliemark J. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. Leuk Lymphoma. 1994;13(1):75-80.
82. Robak T, Bonski JZ, Kasznicki M, et al. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia: efficacy and toxicity in comparison with previous treatment. Eur J Haematol. 2002;69(1):27-36.
83. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995;13(3):570-574.
84. Robak T, Blasinska-Morawiec M, Blonski JZ, et al. The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukemia. Eur J Cancer. 1997;33(14):2347-2351.
85. Karlsson K, Stromberg M, Jonsson V, Mulligan SP, Liliemark J, Juliusson G. Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL): first results from the International Randomized Phase III Trial. Blood [ASH Annual Meeting Abstracts]. 2007;110:630.
86. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: a report of a prospective, randomized, multicenter trial. Blood. 2000;96(8):2723-2729.
87. Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006;108(2):473-479.
88. Robak T, Jamroziak K, Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol. 2010;28(11):1863-1869.
89. Tefferi A, Witzig TE, Reid JM, Li CY, Ames MM. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol. 1994;12(3):569-574.
90. Juliusson G, Elmhorn-Rosenberg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med. 1992;327(15):1056-1061.
91. O'Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med. 1994;330(5):319-322.
92. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet. 2007;370(9583):230-239.
93. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-891.
94. Robak T, Blonski JZ, Wawrzyniak E, et al. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia 2ith 17p13.1/TP53 deletion. Cancer. 2009;115(1):94-100.
95. Saven A, Piro L. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med. 1994;120(9):784-791.
96. Holowiecki J, Grosicki S, Hellmann A, et al. Improved survival in acute myeloid leukaemia patients aged over 40 given cladribine in combination with standard remission induction (DA 3+7) and consolidation treatment (HD AraC): seven year follow-up of prospective, cooperative PALG study. Blood [ASH Annual Meeting Abstracts]. 2006;108:2003.
97. Holowiecki J, Grosicki S, Kyrcz-Krzemien S, et al. Cladribine in combination with standard daunorubicine and cytarabine (DAC) as a remission induction treatment improves the overall survival in untreated adults with AML aged < 60 y contrary to combination including fludarabine (DAF). A multicenter, randomized, phase III PALG AML 1/2004 DAC/DAF/DA study in 673 patients: a final update. Blood [ASH Annual Meeting Abstracts]. 2009;114:2055.
98. Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood. 1999;93(12):4125-4130.
99. Kluin-Nelemens HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270-4276.
100. Klion AD. How I treat hypereosinophilic syndromes. Blood. 2009;114(18):3736-3741.
101. Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005;74(2):117-120. (Pubitemid 40175314)
102. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2- Chlorodeoxyadeonsine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood. 1992;80(3):587-592.
103. Saven A, Lee T, Schlutz M, et al. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol. 1997;15(1):37-43.
104. Sigal D, Saven A. Cladribine in indolent non-Hodgkin's lymphoma. Exp Rev Anticancer Ther. 2008;8(4):535-545.
105. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83(10):2906-2911.
106. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology. 2007:332-338.
107. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993;82(6):1695-1700.
108. Van Den Neste E, Louviaux I, Michaux J, et al. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′- deoxyadenosine. Br J Haematol. 1999;105(1):268-270.
109. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27(2):250-255.
110. Robak T, Blosnki JZ, Gora-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer. 2004;40(3):383-389. (Pubitemid 38121276)
111. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17(8):2454-2460.
112. Chasty RC, Myint H, Oscier DG, et al. Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA). Leuk Lymphoma. 1998;29(3):391-398.
113. Tetreault S, Saven A. Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenstrom macroglobulinemia. Leuk Lymphoma. 2000;37(1):125-130.
114. Blonski JZ, Robak T, Trelinski J, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with cladribine. Blood [ASH Annual Meeting Abstracts]. 2008;112:4179.
115. Robak T, Blasińska-Morawiec M, Krykowski E, Hellmann A, Konopka L. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol. 1997;58(2):109-113.
116. Robak T, Kasznicki M, Bloń ski JZ, Dmoszyńska A, Skotnicki AB. Pure red cell aplasia in patients with chronic lymphocytic leukemia treated with cladribine. Br J Haematol. 2001;112(4):1083-1085.
117. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol. 1994;12(10):2216-2228.
118. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-426.
119. Warzocha K, Krykowski E, Gora-Tybor J, Fronczak A, Robak T. Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma. Leuk Lymphoma. 1996;21(3):343-346.
120. Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood. 1994;84(10):3429-3434.
121. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, in combination with gemcitabine/carboplatin (B/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol [ASCO Annual Meeting Abstract]. 2009;27:3.
122. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14(1):309-317.
123. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas: first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood [ASH Annual Meeting Abstract]. 2007;110:385.